Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health
Reference27 articles.
1. Kalydeco (ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2018.
2. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function;Van Goor;J Cyst Fibros,2014
3. Ivacaftor potentiation of multiple CFTR channels with gating mutations;Yu;J Cyst Fibros,2012
4. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation;De Boeck;J Cyst Fibros,2014
5. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation;Davies;Am J Respir Crit Care Med,2013
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toward responsible clinical n-of-1 strategies for rare diseases;Drug Discovery Today;2023-10
2. Disease severity of people with cystic fibrosis carrying residual function mutations: Data from the ECFS Patient Registry;Journal of Cystic Fibrosis;2023-03
3. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy;Expert Review of Respiratory Medicine;2023-02-01
4. Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine;Pharmaceutics;2023-01-03
5. Effects of elexacaftor–tezacaftor–ivacaftor discontinuation in cystic fibrosis;Respiratory Medicine and Research;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3